The SBS26-positive patients displayed a BRCA1/2 wildtype for the germline and tumor (n = 2), a germline wild type (n = 1), or had a germline BRCA2 mutation (n = 1) and were treated with niraparib (n = 3) or olaparib (n = 1). This evidence concerns the gene BRCA1 and neoplasm.